Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BENOIT C PINEAU

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1619173309
CMS profile
300169
Location
ST. AUGUSTINE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,245.42

116 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,245.42 116

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BENOIT C PINEAU

NPI 1619173309 · CMS profile ID 300169

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ST. AUGUSTINE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619173309?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BENOIT C PINEAU, NPI 1619173309, CMS profile ID 300169. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619173309?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). BENOIT C PINEAU, NPI 1619173309, CMS profile ID 300169. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619173309?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
BENOIT C PINEAU, NPI 1619173309, CMS profile ID 300169, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1619173309?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

116 matching records · $2,245.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 116 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 116.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $22.6606/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998140879 CMS
Janssen Biotech, Inc. $13.1806/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988273763 CMS
ABBVIE INC. $17.7306/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998140877 CMS
ABBVIE INC. $20.0106/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998140875 CMS
Lilly USA, LLC $16.9406/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031285703 CMS
ABBVIE INC. $15.6906/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998140873 CMS
Celgene Corporation $25.5706/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015657099 CMS
Regeneron Healthcare Solutions, Inc. $22.5306/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999368275 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.1106/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057376027 CMS
ABBVIE INC. $14.8606/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998140871 CMS
PFIZER INC. $19.9506/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049531391 CMS
Janssen Biotech, Inc. $12.7306/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988273783 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.7706/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055542603 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.8505/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055542599 CMS
ABBVIE INC. $6.7705/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998140869 CMS
ABBVIE INC. $14.6405/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998140867 CMS
Celgene Corporation $20.7505/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015657087 CMS
Enterra Medical, Inc. $14.4805/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060559423 CMS
Ironwood Pharmaceuticals, Inc $16.9105/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045582139 CMS
Pharmacosmos Therapeutics Inc. $13.8505/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046259603 CMS
INTERCEPT PHARMACEUTICALS, INC. $20.4905/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053808073 CMS
ABBVIE INC. $1.8305/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998140865 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.2805/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055542593 CMS
Regeneron Healthcare Solutions, Inc. $23.8805/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999368269 CMS
Braintree Laboratories, Inc. $19.5204/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006460197 CMS
Merck Sharp & Dohme LLC $16.3204/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048257705 CMS
Fresenius Kabi USA, LLC $24.5204/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060097231 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.3404/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057260871 CMS
Daiichi Sankyo Inc. $21.4904/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006355119 CMS
Ardelyx, Inc. $16.6804/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052958351 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.2504/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057400421 CMS
Celgene Corporation $22.7504/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015657071 CMS
Janssen Biotech, Inc. $12.8804/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988273773 CMS
ABBVIE INC. $5.3104/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998140863 CMS
PFIZER INC. $13.4204/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049129663 CMS
Ironwood Pharmaceuticals, Inc $14.7003/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045563613 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.0803/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055542587 CMS
Merck Sharp & Dohme LLC $14.0503/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048847515 CMS
Celgene Corporation $18.4603/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015657067 CMS
Janssen Biotech, Inc. $13.7903/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988273741 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.3603/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055542581 CMS
ABBVIE INC. $17.3603/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998140861 CMS
Pharmacosmos Therapeutics Inc. $14.3103/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046259595 CMS
INTERCEPT PHARMACEUTICALS, INC. $21.5103/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053808069 CMS
Celgene Corporation $19.1302/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015657063 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.6302/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055542575 CMS
ABBVIE INC. $23.3602/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998140859 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.5102/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055542569 CMS
Regeneron Healthcare Solutions, Inc. $23.5102/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999368263 CMS
ABBVIE INC. $8.8702/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998140857 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,034.45 49
PY2020 $409.47 24
PY2021 $5,633.41 99
PY2022 $2,060.84 102
PY2023 $2,245.42 116
PY2024 $4,830.93 116
PY2025 $24,515.06 148

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $104,124.38 29
PY2024 Principal investigator $139,873.98 42
PY2023 Principal investigator $101,148.91 17
PY2022 Principal investigator $8,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $15,300.00 12/17/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211617847
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $5,000.00 12/17/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211617850
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $2,793.00 12/17/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211617855
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,948.00 12/17/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211617860
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,500.00 12/17/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211617864
Principal investigator 1 Madrigal Pharmaceuticals $2,523.32 11/25/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252845
Principal investigator 1 Madrigal Pharmaceuticals $2,189.74 10/16/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251517
Principal investigator 1 Madrigal Pharmaceuticals $1,567.50 09/18/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250221
Principal investigator 1 Madrigal Pharmaceuticals $500.00 09/04/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249504
Principal investigator 1 Madrigal Pharmaceuticals $2,189.74 08/21/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248862
Principal investigator 1 Madrigal Pharmaceuticals $2,523.32 07/31/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247730
Principal investigator 1 Madrigal Pharmaceuticals $11,475.00 07/31/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247733
Principal investigator 1 Madrigal Pharmaceuticals $325.00 07/31/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247737
Principal investigator 1 Madrigal Pharmaceuticals $10,665.00 07/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246802
Principal investigator 1 Madrigal Pharmaceuticals $175.00 07/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246806
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,597.50 07/09/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282418
Principal investigator 1 Madrigal Pharmaceuticals $2,690.05 05/22/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244396
Principal investigator 1 Madrigal Pharmaceuticals $1,507.50 05/22/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244405
Principal investigator 1 Madrigal Pharmaceuticals $1,118.50 04/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242287
Principal investigator 1 Madrigal Pharmaceuticals $622.50 04/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242291
Principal investigator 1 Madrigal Pharmaceuticals $2,189.74 04/08/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241926
Principal investigator 1 Madrigal Pharmaceuticals $810.00 03/13/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240914
Principal investigator 1 Madrigal Pharmaceuticals $125.00 03/13/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240918
Principal investigator 1 Madrigal Pharmaceuticals $5,010.60 03/06/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240404
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $540.00 03/03/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223275791
Principal investigator 2 Madrigal Pharmaceuticals $1,800.00 02/13/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239721
Principal investigator 1 Madrigal Pharmaceuticals $1,800.00 02/13/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239725
Principal investigator 1 Madrigal Pharmaceuticals $5,213.37 02/06/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239246
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,425.00 01/29/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEA
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) No dispute reported 06/30/2026 1185547211